Document is current
Any future updates will be listed below
-
Authors
Ghiboub, Mohammed https://orcid.org/0000-0002-2095-371X
Koster, Jan
Craggs, Peter D.
Li Yim, Andrew Y. F.
Shillings, Anthony
Hutchinson, Sue
Bingham, Ryan P.
Gatfield, Kelly
Hageman, Ishtu L.
Yao, Gang
O’Keefe, Heather P.
Coffin, Aaron
Patel, Amish
Sloan, Lisa A.
Mitchell, Darren J.
Hayhow, Thomas G.
Lunven, Laurent
Watson, Robert J.
Blunt, Christopher E.
Harrison, Lee A.
Bruton, Gordon
Kumar, Umesh
Hamer, Natalie
Spaull, John R.
Zwijnenburg, Danny A.
Welting, Olaf
Hakvoort, Theodorus B. M.
te Velde, Anje A.
van Limbergen, Johan
Henneman, Peter
Prinjha, Rab K.
de Winther, Menno P. J.
Harker, Nicola R.
Tough, David F.
de Jonge, Wouter J.
-
Funding
Funding for this research was provided by:
H2020 European Research Council (ITN-2014-EID-641665, ITN-2014-EID-641665)
Ministerie van Buitenlandse Zaken (TKI-LSH T2017)
- License Information
-
More Information
Article History
Received: 27 October 2021
Accepted: 28 July 2022
First Online: 19 August 2022
Declarations
:
: The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC-approved protocol. Written informed consent was obtained from each donor, as approved by the UK East of England - Cambridgeshire and Hertfordshire Research Ethics Committee.
: Not applicable.
: PDC, AYFLY, AS, SH, RPB, KG, GY, HPK, AC, AP, LAS, DJM, LL, TGH, RJW, CEB, LAH, GB, UK, NH, JRP, RKP, NRH, and DFT were employed by GSK at the time of conducting this study. MG, JK, ILH, DAZ, OW, TBMH, AATV, JVL, PH, MPJW, and WJDJ were employed by Amsterdam University Medical Centers at the time of conducting this study. GSK has a patent EP2643462B1 related to the therapeutic use of SP140 inhibitors.
